Oil-in-Water Emulsion Prevents Crystallization of Benzoxazinone Active Ingredient
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current topical formulations of 6-ethoxy-7-methoxy-2-(2-methylsulfanylphenyl)-3,1-benzoxazin-4-one are prone to crystallization, making them unstable for prolonged storage and unsuitable for effective treatment of inflammatory skin diseases like Netherton syndrome.
Innovation Solution
A stable topical formulation is developed using an oil-in-water emulsion with 6-ethoxy-7-methoxy-2-(2-methylsulfanylphenyl)-3,1-benzoxazin-4-one, comprising a medium chain triglyceride oil phase, emollients, emulsifiers, and stabilizers, which prevents crystallization and maintains stability at room temperature.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If 6-ethoxy-7-methoxy-2-(2-methylsulfanylphenyl)-3,1-benzoxazin-4-one is formulated in conventional topical preparations, then the active ingredient can be delivered to the skin, but the formulation becomes unstable and forms needle-shaped crystals during storage
Solution Approach 1:
The patent employs solubilizing agents (such as ethanol, propylene glycol, or cremophor) as intermediary substances that mediate between the hydrophobic active ingredient and the aqueous formulation base. These intermediaries prevent crystallization by maintaining the active ingredient in a dissolved or dispersed state throughout storage, thereby resolving the contradiction between formulation stability and crystallization prevention.
Solution Approach 2:
The patent utilizes pH adjustment (typically to acidic ranges of pH 3-6) and temperature control during preparation and storage as parameter changes to prevent crystallization. By optimizing these physical-chemical parameters, the formulation maintains stability without forming needle-shaped crystals, thus resolving the contradiction between reliability and compositional stability.
2Quantity of substance
If the formulation uses high concentration of active ingredient to improve treatment effectiveness, then therapeutic efficacy increases, but crystallization risk increases making the formulation unstable
Solution Approach 1:
The patent employs solubilizing agents (such as ethanol, propylene glycol, or cremophor) as intermediary substances that mediate between the hydrophobic active ingredient and the aqueous formulation base. These intermediaries prevent crystallization by maintaining the active ingredient in a dissolved or dispersed state throughout storage, thereby resolving the contradiction between formulation stability and crystallization prevention.
Solution Approach 2:
The patent creates a composite formulation system combining the active ingredient with multiple excipients including solubilizing agents, emulsifiers, and pH buffers. This composite approach allows higher concentrations of the active ingredient to be maintained in solution without crystallization, thus resolving the contradiction between quantity of substance and reliability.
3Quantity of substance
If conventional solvents are used to dissolve the active ingredient, then solubility is achieved, but the formulation becomes unsuitable for topical application to skin
Solution Approach 1:
The patent employs solubilizing agents (such as ethanol, propylene glycol, or cremophor) as intermediary substances that mediate between the hydrophobic active ingredient and the aqueous formulation base. These intermediaries prevent crystallization by maintaining the active ingredient in a dissolved or dispersed state throughout storage, thereby resolving the contradiction between formulation stability and crystallization prevention.
Solution Approach 2:
The patent utilizes pH adjustment (typically to acidic ranges of pH 3-6) and temperature control during preparation and storage as parameter changes to prevent crystallization. By optimizing these physical-chemical parameters, the formulation maintains stability without forming needle-shaped crystals, thus resolving the contradiction between reliability and compositional stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation effectively prevents crystallization of 6-ethoxy-7-methoxy-2-(2-methylsulfanylphenyl)-3,1-benzoxazin-4-one, ensuring a stable and effective topical treatment for inflammatory skin diseases, particularly Netherton syndrome, by maintaining solubility and preventing needle-shaped crystal formation.
Implementation Method 1
6-Ethoxy-7-methoxy-2-(2-methylsulfanylphenyl)-3,1-benzoxazin-4-one has low solubility in water but can be dissolved in various organic solvents
Implementation Method 2
The present invention relates to a topical formulation of 6-ethoxy-7-methoxy-2-(2-methylsulfanylphenyl)-3,1-benzoxazin-4-one in an oil-in-water emulsion
Data Source
AI summary
The present invention provides topical formulations of 6-ethoxy-7-methoxy-2-(2-methylsulfanylphenyl)-3,1-benzoxazin-4-one in the form of oil-in-water emulsions and their use in the in prophylaxis, prevention, and/or treatment of inflammatory skin diseases, especially Netherton syndrome.